Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Zolacabtagene autoleucel by Bristol-Myers Squibb for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Relapsing Multiple Sclerosis (RMS). According...
Zolacabtagene autoleucel by Bristol-Myers Squibb for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Primary Progressive Multiple Sclerosis (PPMS)....
Zolacabtagene autoleucel by Bristol-Myers Squibb for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According...
Zolacabtagene autoleucel by Bristol-Myers Squibb for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
Zolacabtagene autoleucel by Bristol-Myers Squibb for Follicular Lymphoma: Likelihood of Approval
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma. According to GlobalData,...